Blinatumomab Benefit Assessment for ALL and Hea...
The German Federal Joint Committee (G-BA) published a Blinatumomab benefit assessment under §35a SGB V. It evaluates its use as consolidation therapy in adults with newly diagnosed Philadelphia chromosome-negative (Ph−), CD19-...